GenVec president and ceo to retire

US firm hires recruitment firm to find a successor

GenVec, a US biopharmaceutical company that uses differentiated, proprietary technologies to create therapeutics and vaccines, says Paul Fischer plans to retire as president and chief executive. Dr Fischer will continue in the role until a successor is named and the ceo transition is complete. The Board will use Spencer Stuart, an executive search firm, to advise it on potential candidates.

Fischer has been with the Gathersburg, MD firm for 15 years.

You may also like

Pharmaceutical

Optimising process steps and performance with agitated Nutsche filter-dryers

Agitated Nutsche filter dryers (ANFD) streamline solid-liquid separation by performing filtration, dewatering, and drying in a single sealed vessel; an enormous boon in fine chemicals and pharmaceutical production
Design & Build

Cleanroom Technology launches global cleanroom awards

Introducing the Cleanroom Technology Awards, the global benchmark for cleanroom excellence
Sustainability

ACG Packaging Materials becomes first pharma packaging firm to join WEF Lighthouse Network

The company has joined the World Economic Forum’s Global Lighthouse Network after its Shirwal facility was named a Lighthouse site, making it the world’s first pharmaceutical packaging company to receive the recognition for smart, sustainable manufacturing
Pharmaceutical

testo Saveris 1 update automates environmental monitoring workflows for pharma compliance

New features include automated workflows for efficient environmental monitoring, approvals for secure and compliant changes, and more flexible control of webhooks, as well as further improvements in performance, transparency and usability
Regulatory

Hims & Hers backs down on oral GLP-1 copycat after FDA pressure

Facing threats of legal action from Wegovy manufacturer Novo Nordisk and an FDA probe, the health and wellness company has decided to abandon its plans to offer a GLP-1 copycat
Pharmaceutical

PharmNovo enhances its board ahead of Phase II development

The new board members bring complementary experience in drug development, clinical execution and partnering, supporting the company’s continued progress and dialogue with potential partners
Research & Development

AdvanCell partners with 48Hour Discovery on peptide-based lead-212 radiotherapeutic

The pair will develop a novel peptide-based Lead-212 radiotherapeutic targeting a gastrointestinal cancer with significant unmet need, strengthening AdcanCell's pipeline of differentiated targeted alpha therapies
Subscribe now